Angiogenesis in the atherosclerotic plaque

Area of Science:

• Cardiovascular biology
• Vascular medicine
• Angiogenesis research

Background:

• Atherosclerosis, a leading cause of death, involves arterial cholesterol buildup and inflammation.
• Neovascularization within atherosclerotic lesions significantly impacts plaque progression and stability.
• Current understanding highlights both general and atherosclerosis-specific factors in angiogenic processes.

Purpose of the Study:

• To investigate the role of neovascularization in atherosclerotic plaque development and destabilization.
• To evaluate the potential of anti-angiogenic agents in managing atherosclerosis.
• To address the cardiovascular safety concerns associated with anti-angiogenic therapies.

Main Methods:

• Review of existing literature on atherosclerosis and angiogenesis.
• Analysis of data from animal models investigating anti-angiogenic agents.
• Examination of clinical trial outcomes for anti-angiogenic drugs in cancer therapy and their cardiovascular effects.

Main Results:

• Neovascularization is a critical factor in atherosclerotic plaque growth, instability, and thromboembolic events.
• Anti-angiogenic therapies have demonstrated efficacy in reducing atherosclerosis progression in preclinical studies.
• Clinical application of anti-angiogenic drugs, particularly anti-VEGF/VEGFR agents, has been associated with adverse cardiovascular events.

Conclusions:

• Neovascularization is a key therapeutic target for atherosclerosis.
• Further investigation is crucial to develop safe and effective anti-angiogenic strategies for cardiovascular disease.
• Balancing anti-angiogenic efficacy with cardiovascular safety remains a significant challenge.